Adela will provide an advanced blood test to detect multiple high-morbidity, high-mortality diseases before symptoms occur, and to enable management through the entire care continuum. Adela’s ability to detect many diseases through a single platform with best-in-class performance sets it apart from other liquid biopsy companies.